TBRG:NASDAQTruBridge, Inc. Analysis
Data as of 2026-07-17 - not real-time
$26.24
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
TruBridge trades at $26.24, just below the short‑term resistance of $26.25 and above the immediate support of $26.04. The stock is in a bullish price trend (20‑day SMA > 50‑day SMA > 200‑day SMA) but technical signals are mixed: RSI is at an extreme 79 indicating overbought conditions, while the MACD histogram is negative and the signal line is bearish. Valuation metrics are strained – a trailing P/E of 90× dwarfs the industry average of 29×, yet the forward P/E collapses to 8.9× thanks to a projected EPS jump from $0.29 to $2.96. The DCF model suggests a fair value of $23.46, implying the market is pricing the stock about 3% above intrinsic value. On the fundamentals side, revenue is flat (‑1.1% growth) and margins are thin (operating margin 4.7%, profit margin 1.3%), while leverage is high with a debt‑to‑equity near 94% and a $169 M debt load versus $35 M cash.
The company faces material headlines: a securities‑class‑action investigation, insider benefit concerns, and the recent approval of a merger with IKS. These legal and merger‑related uncertainties add downside risk despite the “Extreme Greed” market sentiment (Fear‑Greed Index 89.55). Investors must weigh the short‑term overbought technical picture and legal cloud against the longer‑term earnings upside implied by the forward metrics and the merger’s potential synergies.
The company faces material headlines: a securities‑class‑action investigation, insider benefit concerns, and the recent approval of a merger with IKS. These legal and merger‑related uncertainties add downside risk despite the “Extreme Greed” market sentiment (Fear‑Greed Index 89.55). Investors must weigh the short‑term overbought technical picture and legal cloud against the longer‑term earnings upside implied by the forward metrics and the merger’s potential synergies.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- RSI in overbought territory (79) signaling potential pullback
- Bearish MACD histogram and signal line
- Legal uncertainty from securities class‑action investigation
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Approved IKS merger offering strategic synergies
- Forward P/E of 8.9× indicating significant earnings upside
- Improving cash flow generation (operating cash flow $46.7 M)
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High leverage (debt‑to‑equity ~94%) constraining financial flexibility
- Thin profit margins limiting organic growth
- Stable demand for revenue‑cycle management services in healthcare
Key Metrics & Analysis
Financial Health
Revenue Growth-1.10%
Profit Margin1.27%
P/E Ratio90.5
ROE2.54%
ROA3.24%
Debt/Equity94.27
P/B Ratio2.2
Op. Cash Flow$46.7M
Free Cash Flow$37.2M
Industry P/E29.0
Technical Analysis
TrendBullish
RSI79.1
Support$26.04
Resistance$26.25
MA 20$26.18
MA 50$26.02
MA 200$21.68
MACDBearish
VolumeDecreasing
Fear & Greed Index89.55
Valuation
Fair Value$23.46
Target Price$25.44
Upside/Downside-3.06%
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.65
Volatility1.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.